Professor Robert Murphy (Robert L. Murphy), MD, Director of the Center for Global Health and world famous expert in the field of antiretroviral therapy, has joined the Scientific Advisory Board of Viriom, member of ChemRar High-Tech Center, as the Head of Clinical Development.
Currently, Robert Murphy directs the Center for Global Health at Northwestern University (Illinois, USA). He is also a professor at the University of Pierre et Marie Curie (Paris, France). Professor Murphy has devoted himself to viral infections research, the development of HIV and AIDS vaccines, as well as the fight against AIDS, tuberculosis and malaria in Africa.
Professor Murphy is a Special Adviser to the President's program to combat AIDS in Nigeria, sponsored by the Harvard School of Public Health. Dr. Murphy supervised the opening of 42 clinics, as part of this program, where over 75 thousand patients with HIV and AIDS are currently being treated. In addition, he is a consultant for antiretroviral educational projects in Senegal, supported by the US National Health Institutes.
Professor Murphy is also a leading researcher of the National Institute of Allergy and Infectious Diseases, he is a member of a group of AIDS clinical research specialists at Northwestern University. In AIDS GCRS Robert Murphy has held various senior positions, including Member of the Scientific Council, Strategic and Executive Committees. Professor Murphy is a member of many medical societies and boards of directors of a number of non-profit organizations. He is also a member of International AIDS Educational Program and has founded an organization aimed at fighting AIDS in the Midwest.
"Viriom conducts clinical trials of the drug VM-1500 which belongs to a class of non-nucleoside HIV reverse transcriptase inhibitors. I am following the progress of the drug in the clinic with great interest," said Dr. Murphy. "Judging by our results of preclinical and clinical (Phase 1a) research, VM-1500 can become the best drug in its class."
Irina Tyrnova, General Manager of Viriom added, "We are very honored that Professor Murphy joined Viriom's Scientific Advisory Board. We look forward to this collaboration and hope that the remarkable experience of Professor Murphy will allow us to make significant progress in treating AIDS and HIV."
Viriom Ltd. is a member of ChemRar group of companies involved in developing innovative antiviral drugs and combinations, treatment methods, and diagnostics. Viriom conducts scientific research in Russia, tapping into the experience and knowledge of Russian scientists, and abroad within the framework of a broad international partnership. The ChemDiv Research Institute is Viriom's major partner in pre-clinical and clinical research. Clinical studies within Russia are conducted at regional centers and on campus of the Moscow City Center for Preventing and Treating AIDS. Among Viriom’s international partners are Roche, Fox Chase Cancer Center (Philadelphia, PA), The Scripps Research Institute (San Diego, CA), Moscow Physics and Technology Institute, and M.P. Chumakov Institute for Poliomyelitis and Viral Encephalitis (Moscow, Russia). The "Viriom" project was approved by the Presidential Commission on Modernization of the Russian Federation. www.viriom.com